Does long-term partial sodium channel blockade alter disease progression in MS? Evidence from a retrospective study

Irish Journal of Medical Science

Volumn 183, Issue 1, 2014, Pages 117-121

  Counihan, T J ^a,c   Duignan, J A ^a   Gormley, G ^a   Saidha, S ^b   Dooley, C ^a   Newell, J ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

Carbamazepine; Multiple sclerosis; Neuroprotection; Sodium channels

Indexed keywords

AMITRIPTYLINE; CARBAMAZEPINE; GABAPENTIN; PREGABALIN; SODIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL; NEUROPROTECTIVE AGENT; SODIUM CHANNEL BLOCKING AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NERVE FIBER; RETROSPECTIVE STUDY; TREATMENT DURATION; DISABILITY; METABOLISM; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

ADULT; CARBAMAZEPINE; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SODIUM CHANNEL BLOCKERS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84893743613     PISSN: 00211265     EISSN: 18634362     Source Type: Journal    
DOI: 10.1007/s11845-013-1042-7     Document Type: Article

References (12)

1. Waxman SG (2008) Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis: current status. Nat Clin Pract Neurol 4:159-169 (Pubitemid 351356596)
2. Lo AC, Saab CY, Black JA, Waxman SG (2003) Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. J Neurophysiol 90:3566-3571 (Pubitemid 37430046)
3. Kapoor R (2008) Sodium channel blockers and neuroprotection in multiple sclerosis using lamotrigine. J Neurol Sci 274:54-56
4. Craner MJ, Damarjian TG, Liu S, Hains BC et al (2005) Sodium channels contribute to microglia/macrophage activation and function in EAE and MS. Glia 49:220-229 (Pubitemid 40188501)
5. Black JA, Liu S, Carrithers M, Carrithers LM, Waxman SG (2007) Exacerbation of EAE after withdrawal of phenytoin and carbamazepine. Ann Neurol 62:21-33 (Pubitemid 47235277)
6. Thompson AJ, Toosy AT, Ciccarelli O (2010) Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions. Lancet Neurol 9:1182-1199
7. Kapoor R, Furby J, Hayton T et al (2010) Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol 9:681-688
8. Roxburgh RHSR, Seaman SR, Masterman T et al (2005) Multiple Sclerosis Severity score: using disability and disease duration to rate disease severity. Neurology 64:1144-1151
9. D'Agostino RB Jr (1998) Tutorial in biostatistics: propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265-2281 (Pubitemid 28466823)
10. Rosenbaum PR (2010) Design of observational studies. Springer, New York
11. R Development Core Team (2008) R: A language and environment for statistical computing. r foundation for statistical computing, Vienna, Austria. ISBN 3-900051-07-0
12. Hansen BB, Olsen Klopfer S (2006) Optimal full matching and related designs via network flows. J Comput Graph Stat 153:609-627 (Pubitemid 44554199)